The Medicaid and CHIP Payment and Access Commission agreed to recommend that Congress give states a 180-day grace period to evaluate a new drug's effectiveness before deciding whether to cover that drug. The commission's members also want lawmakers to eliminate a cap on Medicaid drug rebates.
MACPAC wants states to have more time to make drug coverage decisions
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.